Results 41 to 50 of about 8,460 (122)

Budesonide MMX: efficacy and safety profile in the treatment of ulcerative colitis

, 2019
Introduction: Ulcerative colitis is an idiopathic, chronic inflammatory disease of the colonic mucosa. Its clinical course is unpredictable, marked by alternating periods of exacerbation and remission.
Calabrese C., Gionchetti P., Salice M., Rizzello F., Privitera Hrustemovic H.   +4 more
core   +1 more source

From Pharmaceutical to Biophysical Therapies: New Horizons in Inflammatory Bowel Disease Management

JCC Plus, Volume 1, Issue 2, March 2026.
Important limitations exist in the current pharmacological landscape of Inflammatory Bowel Disease (IBD), such as variable response rates and treatment‐limiting adverse effects. In this review, we perform a critical assessment of the current literature on novel multimodal biophysical approaches showing alternative mechanisms of action to, and potential
Benedetta Ricchi, Alejandra A. Carriles, Samuel Elias Pineda Chavez, Stefanos Bonovas, Arianna Dal Buono, Cristina Bezzio, Alessandro Armuzzi, Stefania Vetrano   +7 more
wiley   +1 more source

UEG Week 2022 Poster Presentations

, 2022
United European Gastroenterology Journal, Volume 10, Issue S8, Page 473-1092, October 2022.
wiley   +1 more source

Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study.

, 2016
BACKGROUND and AIMS: Budesonide is a corticosteroid with minimal systemic corticosteroid activity due to first-pass hepatic metabolism. Budesonide MMX® is a once-daily oral formulation of budesonide that extends budesonide release throughout the colon ...

core   +1 more source

Barriers Associated With Treatment Nonadherence in Mexican Patients With Ulcerative Colitis: The Role of Medication Beliefs

Journal of Clinical Pharmacy and Therapeutics, Volume 2026, Issue 1, 2026.
Background The adherence to medical treatment is important in patients with inflammatory bowel disease (IBD) in order to maintain remission and avoid complications. The aim of this study was to identify the demographics, clinical features, and patients’ barriers associated with nonadherence to medical treatment in Mexican patients with ulcerative ...
Ana Fresán, Karen A. Yamamoto-Rodríguez, Katia M. Yamamoto-Rodríguez, Jesus K. Yamamoto-Furusho, Anjali Chauhan   +4 more
wiley   +1 more source

Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children. [PDF]

, 2013
BACKGROUND: Asthma is characterised by chronic inflammation of the airways and recurrent exacerbations with wheezing, chest tightness and cough. Treatment with inhaled steroids and bronchodilators often results in good control of symptoms, prevention of ...
Mindus, SM, Ferrara, G, Ferrara, G,, Kew, KM, Karner, C, Mindus SM, Kew KM, Karner C, FERRARA, Giovanni   +8 more
core   +1 more source

Management of paediatric ulcerative colitis, part 1: Ambulatory care—An updated evidence‐based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation

Journal of Pediatric Gastroenterology and Nutrition, Volume 81, Issue 3, Page 765-815, September 2025.
Abstract Objectives Despite advances in the management of ambulatory paediatric ulcerative colitis (UC), challenges remain as many patients are refractory to therapy and some require colectomy. The aim of these guidelines is to provide an update on optimal care for UC through detailed recommendations and practice points. Methods These guidelines are an
Eytan Wine, Marina Aloi, Stephanie Van Biervliet, Jiri Bronsky, Javier Martín di Carpi, Marco Gasparetto, Laura Gianolio, Hannah Gordon, Iva Hojsak, Alexandra S. Hudson, Séamus Hussey, Johan van Limbergen, Erasmo Miele, Lorenzo Norsa, Ola Olén, Gianluca Pellino, Patrick van Rheenen, Lissy de Ridder, Richard K. Russell, Dror S. Shouval, Eunice Trindade, Dan Turner, David C. Wilson, Anat Yerushalmy Feler, Amit Assa   +24 more
wiley   +1 more source

Supplementary Material for: Predictors of Inadequate Response to Budesonide Multimatrix in Real-World Patients with Ulcerative Colitis

, 2019
Background: Budesonide multimatrix (MMX) system has been approved for the induction of remission in patients with active, mild to moderate ulcerative colitis (UC), and offers potential safety benefits over more commonly utilized corticosteroid therapies.
Greenberg S. (6938831), Herfarth H.H. (6481682), Barnes E.L. (6481679)   +2 more
core   +1 more source

Development of novel zero-order release budesonide tablets for the treatment of ileo-colonic inflammatory bowel disease and comparison with formulations currently used in clinical practice [PDF]

, 2019
Up to 50% of Crohn's disease and ulcerative colitis patients suffer from ileo-colonic inflammation. Topically delivered budesonide is an effective treatment but in vitro as well as clinical data suggest that oral formulations currently used in clinical ...
Kosterink, Jos G W; id_orcid, Kosterink, Jos G.W.; id_orcid, Gareb, Bahez, Dijkstra, Gerard, Frijlink, Henderik W.; id_orcid, Frijlink, Henderik W, Gareb, Bahez; id_orcid, Dijkstra, Gerard; id_orcid, Kosterink, Jos G W, Frijlink, Henderik W; id_orcid   +9 more
core   +1 more source

The Use of Budesonide MMX to Induce Remission in Active, Moderate to Mild Ulcerative Colitis: A Systematic Review [PDF]

, 2013
Background: Ulcerative colitis (UC), a type of inflammatory bowel disease characterized by diffuse colonic mucosal inflammation, accounts for over 250k physician visits annually with direct medical costs alone exceeding 4 billion dollars annually.
Potter, Terence
core